Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: Systematic review and meta-analysis

Translational Research

Volumn 164, Issue 6, 2014, Pages 444-451

  Bruzzese, Dario ^a   Mazzarella, Claudia ^a   Ferro, Matteo ^b   Perdonà, Sisto ^c   Chiodini, Paolo ^d   Perruolo, Giuseppe ^a   Terracciano, Daniela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AREA UNDER THE CURVE; CANCER DIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; MALE; META ANALYSIS; OBSERVATIONAL STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; QUALITY CONTROL; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TASK PERFORMANCE; BIOPSY; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC;

BIOPSY; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84910684085     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.06.006     Document Type: Review

References (28)

1. F.H. Schroder, and M.J. Roobol Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer Curr Opin Urol 19 2009 227 231
2. L.J. Sokoll, Y. Wang, and Z. Feng [-2]Proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study J Urol 180 2008 539 543 discussion 43
3. S.D. Mikolajczyk, L.S. Marks, A.W. Partin, and H.G. Rittenhouse Free prostate-specific antigen in serum is becoming more complex Urology 59 2002 797 802
4. S.D. Mikolajczyk, W.J. Catalona, and C.L. Evans Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer Clin Chem 50 2004 1017 1025
5. B.V. Le, C.R. Griffin, and S. Loeb [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2010 1355 1359
6. F.H. Jansen, R.H. van Schaik, and J. Kurstjens Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921 927
7. G. Guazzoni, L. Nava, and M. Lazzeri Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting Eur Urol 60 2011 214 222
8. G. Guazzoni, M. Lazzeri, and L. Nava Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer Eur Urol 61 2012 455 466
9. W.J. Catalona, A.W. Partin, and M.G. Sanda A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650 1655
10. X. Filella, and N. Gimenez Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis Clin Chem Lab Med 51 2013 729 739
11. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
12. P. Whiting, A.W. Rutjes, J.B. Reitsma, P.M. Bossuyt, and J. Kleijnen The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Med Res Methodol 3 2003 25
13. P.F. Whiting, A.W. Rutjes, and M.E. Westwood QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies Ann Intern Med 155 2011 529 536
14. M.M. Leeflang, J.J. Deeks, C. Gatsonis, and P.M. Bossuyt Systematic reviews of diagnostic test accuracy Ann Intern Med 149 2008 889 897
15. C.M. Rutter, and C.A. Gatsonis A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations Stat Med 20 2001 2865 2884
16. R.M. Harbord, J.J. Deeks, M. Egger, P. Whiting, and J.A. Sterne A unification of models for meta-analysis of diagnostic accuracy studies Biostatistics 8 2007 239 251
17. V.A. Moyer Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 120 134
18. A.W. Roddam, M.J. Duffy, and F.C. Hamdy Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis Eur Urol 48 2005 386 399 discussion 98-9
19. S. Hori, J.S. Blanchet, and J. McLoughlin From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer BJU Int 112 2012 717 728
20. A. Sottile, C. Ortega, and A. Berruti A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy Oncol Lett 3 2012 819 824
21. M.B. Nichol, J. Wu, J. Huang, D. Denham, S.K. Frencher, and S.J. Jacobsen Cost-effectiveness of Prostate Health Index for prostate cancer detection BJU Int 110 2011 353 362
22. M.M. Leeflang Systematic reviews and meta-analyses of diagnostic test accuracy Clin Microbiol Infect 20 2014 105 113
23. S.S. Salami, F. Schmidt, and B. Laxman Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer Urol Oncol 31 2013 566 571
24. S. Perdona, D. Bruzzese, and M. Ferro Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy Prostate 73 2013 227 235
25. M. Ferro, D. Bruzzese, and S. Perdona Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml PLoS ONE 8 2013 e67687
26. M. Lazzeri, A. Haese, and A. de la Taille Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study Eur Urol 63 2013 986 994
27. S. Loeb, L.J. Sokoll, and D.L. Broyles Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration J Urol 189 2013 1702 1706
28. C.F. Ng, P.K. Chiu, N.Y. Lam, H.C. Lam, K.W. Lee, and S.S. Hou The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL Int Urol Nephrol 46 2014 711 717